Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uchimoto Taizo, Iwatsuki Kengo, Komura Kazumasa, Fukuokaya Wataru, Adachi Takahiro, Hirasawa Yosuke, Hashimoto Takeshi, Yoshizawa Atsuhiko, Saruta Masanobu, Fujimoto Saizo, Minami Takafumi, Yamamoto Yutaka, Yamazaki Shogo, Takai Tomoaki, Sakamoto Moritoshi, Nakajima Yuki, Nishimura Kazuki, Maenosono Ryoichi, Tsujino Takuya, Nakamura Ko, Fukushima Tatsuo, Nishio Kyosuke, Yoshikawa Yuki, Yamamoto Shutaro, Iwatani Kosuke, Urabe Fumihiko, Mori Keiichiro, Yanagisawa Takafumi, Tsuduki Shunsuke, Takahara Kiyoshi, Inamoto Teruo, Fujita Kazutoshi, Kimura Takahiro, Ohno Yoshio, Shiroki Ryoichi, Azuma Haruhito
Аннотация
METHODS: Data from the ULTRA-Japan study cohort from five academic institutes (496 mHSPC patients) were retrospectively analyzed.
RESULTS: The median overall survival (OS) in the total cohort was 80 months with a median follow-up of 18 months. Of 496 patients, 332 (67%), 82 (16.5%), and 82 (16.5%) were treated with first-line abiraterone acetate + prednisone, enzalutamide, and apalutamide, respectively. During the follow-up, a total of 155 (31%) were diagnosed with mCRPC with a median TTCR of 10 months. In those 155 patients, TTCR > 12 months is an independent predictor of longer OS from the first-line ARSIs. Cox regression analysis of the TTCR from initiating first-line ARSI in 496 mHSPC patients revealed three variables as independent predictors of shorter TTCR, including Gleason's score (GS) ≥ 9, the extent of disease (EOD) ≥ 2, and the presence of liver metastasis.
CONCLUSION: Our results indicate that mHSPC patients with those three features are likely to have primary resistance to first-line ARSIs (doublet therapy), thus requiring consideration of other options, such as the recent triplet approach.